Jan 25, 2018 7:00am EST Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries
Jan 08, 2018 7:40am EST Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings
Jan 03, 2018 7:00am EST Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH
Dec 18, 2017 7:00am EST Can-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson
Nov 27, 2017 7:30am EST Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update
Nov 17, 2017 7:00am EST Can-Fite’s Former Subsidiary OphthaliX Successfully Completes Merger with Wize Pharma
Oct 30, 2017 9:50am EDT Can-Fite Announces Enrollment of First Patient in its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis
Oct 17, 2017 7:00am EDT Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis
